Drug intelligence / Profile preview

Bronquitis F125 Plus

Development stage: Unknown
Lead developer: FARVET
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Ocular, Intranasal, Oral

Overview

Bronquitis F125 Plus is a live attenuated lyophilized vaccine developed by FARVET for the prevention of Avian Infectious Bronchitis in poultry. It specifically targets the Massachusetts strain of the Infectious Bronchitis Virus (IBV). The vaccine works by stimulating an active immune response against the virus, providing protection against respiratory, reproductive, and renal symptoms associated with IBV infection. It is typically administered to broiler, breeder, and layer flocks via ocular, nasal, or drinking water routes to ensure broad protection within the flock.

Brand names: Bronquitis F125 Plus
Other names: Bronquitis F125 Plus-FARVETInfectious Bronchitis Virus Massachusetts strain vaccine

Beyond the preview

Go deeper on Bronquitis F125 Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bronquitis F125 Plus.

Explore the full profile